A PYMNTS Company

Egypt’s Competition Watchdog Wants To Stop Cleopatra-Alameda Merger

By  |  February 6, 2020

The Egyptian Competition Authority (ECA) has called on the health ministry to stop a potential merger between Cleopatra Hospitals Group, one of Egypt’s largest private hospital groups, and Alameda Healthcare, claiming the deal constitutes a monopolistic practice that would negatively impact people’s rights and the country’s economy, a source at the authority said.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The two groups are currently in talks over a potential merger that would result in a giant unit with around 2,000 beds, the ECA official, who requested anonymity, told Ahram Online on Thursday, January 6.

    In a letter sent to the health ministry, the competition watchdog warned that the merger would raise the price of medical services offered to patients and limit their options for access to healthcare services at reasonable prices. It added that the deal would create a “dominant entity” that would hamper the entry of new investors into the Egyptian healthcare sector.

    The Cleopatra Hospitals Group owns six of Cairo’s most prominent private hospitals, including Cleopatra, Cairo Specialised, Nile Badrawi, Al Shorouk, Queens, and ElKateb hospitals.

    Alameda Healthcare owns As-Salam International Hospital and Dar Al-Fouad Hospital in 6 October and Nasr City, as well as a number of medical laboratories and rehabilitation centres.

    The agency called on the ministry to apply a 2014 decision which stipulates that the sale or change of the legal structure of private hospitals and pharmaceutical firms requires approval from the ministry after ensuring it would not undermine patients’ rights or affect their access to health services.

    Full Content: Ahram Online

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.